<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689843</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P-9145-4025</org_study_id>
    <nct_id>NCT02689843</nct_id>
  </id_info>
  <brief_title>Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS</brief_title>
  <acronym>AntiPCO</acronym>
  <official_title>Effects of Treatment With Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Serum Inflammatory Markers in Patients With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effects of three-month course of treatment
      modalities (Cyproterone compound-Spironolactone, Metformin and Pioglitazone) in patients with
      polycystic ovary syndrome (PCOS) on markers of inflammation [serum complement, homocysteine
      and high sensitive C-reactive protein (hs-CRP)] levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is estimated to affect up to10% of women of reproductive
      age, making it one of the most common endocrine disorders in this population. PCOS is
      associated with a broad range of adverse sequel, including hypertension, dyslipidemia,
      insulin resistance, hyperandrogenaemia, gestational and type 2 diabetes,which ultimately
      increase the cardiovascular morbidity in these patients. Also PCOS is increasingly recognized
      as a component of the metabolic syndrome. Management depends on symptoms or the source of
      androgen excess. Several treatment options are available, which allows for an individualized
      approach. Spironolactone is the safest potent available antiandrogen. It is effective in
      lowering the hirsutism score by approximately one third, although considerable individual
      variations exist. Other antiandrogens used to treat hirsutism and hirsutism equivalents
      include cyproterone acetate that has weak antiglucocorticoid effects. Metformin and
      thiazolidinediones, are promising adjuncts for treating PCOS. Although both of them increase
      insulin sensitivity, but their mechanism of action differ.

      Serum complement, homocysteine and C-reactive protein (CRP) levels have been reported to be
      linked with insulin resistance.

      The investigators want to measure serum complement, homocysteine and hs-CRP levels in
      patients with PCOS before and after three-month course of treatment with Cyproterone
      compound-Spironolactone (CC-S), metformin (M) and pioglitazone (P).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum C3 level</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum C4 level</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum total Testosterone level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free Testosterone level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Dehydroepiandrosterone sulfate (DHEAS) level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum follicle stimulating hormone (FSH) level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum luteinizing hormone (LH) level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Sugar (FBS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum Insulin level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum homocysteine level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum high sensitive C-reactive protein (hs-CRP)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Cyproterone compound + Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1500 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 30 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproterone compound + Spironolactone</intervention_name>
    <description>Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily</description>
    <arm_group_label>Cyproterone compound + Spironolactone</arm_group_label>
    <other_name>CC-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500mg three times daily</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30mg once daily</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-35 years

          -  Diagnosis of Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria 2003
             (two out of three required):

               1. Oligomenorrhea or anovulation

               2. Clinical and/or biochemical signs of hyperandrogenism

               3. Polycystic ovaries (by ultrasound)

        Exclusion Criteria:

          -  Smoking

          -  Pregnancy

          -  Diabetes mellitus

          -  Renal failure (serum creatinine &gt;1.5)

          -  Congenital adrenal hyperplasia

          -  Hyper or hypothyroidism

          -  Sex hormone therapy or antiandrogen therapy during the last three months

          -  Unexplained serum alanin aminotransferase (ALT) elevation more than 2.5 times above
             normal range

          -  Any systemic or febrile illnesses

          -  Use of glucocorticoid or anti-inflammatory drugs during the last three months

          -  Androgen secreting tumor

          -  Malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mesbah Shams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gholamhossein R Omrani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Motahhari Clinic, Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mesbah Shams, MD</investigator_full_name>
    <investigator_title>Associate professor of internal medicine and endocrinology</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Complement system proteins</keyword>
  <keyword>Homocysteine</keyword>
  <keyword>C-Reactive Protein</keyword>
  <keyword>Cyproterone</keyword>
  <keyword>Ethinyl Estradiol</keyword>
  <keyword>Androgen Antagonists</keyword>
  <keyword>Metformin</keyword>
  <keyword>Thiazolidinediones</keyword>
  <keyword>Pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

